The drug lowered two key inflammation signals in the blood by nearly half, which may help calm down the body’s harmful immune response in the arteries.

Pro

Against

Evidence from Studies

Supporting (0)

Community contributions welcome

No supporting evidence found

Contradicting (1)

Community contributions welcome

A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice

Randomized Controlled Trial

Animal

2023

The study shows that the drug MPE-298 helps reduce plaque buildup in mice, which might mean less inflammation, but it never measured the specific inflammation markers (IL-1β and TNF-α) mentioned in the claim, so we can't say those numbers are true.

Source Study

A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice

Score: 12

DOI: 10.3389/fphar.2023.1204905

Similar Assertions

The drug didn’t lower the mice’s overall cholesterol, so its benefits must come from something else—like reducing inflammation or cell death in plaques.

89%

The mice didn’t gain or lose weight or eat differently with the drug, so the benefits aren’t just because they were eating less or changing their metabolism.

85%

The drug didn’t affect blood sugar or fat levels in the blood, so its benefits aren’t due to improving how the body handles sugar or fat.

84%

Mice treated with the drug had much smaller dead-cell areas in their artery plaques—almost half as big—which might mean their plaques are less likely to break open.

80%

The drug lowered the levels of two proteins in the arteries that are known to break down plaque structure, which might help keep plaques from bursting.

79%